[ 5 ] Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma[J]. Leukemia, 2006, 20(9): 1467-1473.
[2]
[ 1 ] Rossi M, Di Martino MT, Morelli E, et al. Molecular targets for the treatment of multiple myeloma[J]. Curr Cancer Drug Targets, 2012, 12(7): 757-767.
[3]
[ 2 ] Schecter J, Lentzsch S. Multiple myeloma: defining the high-risk patient and determining the optimal treatment strategy[J]. Curr Hematol Malig Rep, 2013, 8(4): 277-283.
[ 8 ] Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2013, 88(3): 226-235.
[9]
[ 9 ] Adams J. The proteasome: a suitable antineoplastic target[J]. Nat Rev Cancer, 2004, 4(5): 349-360.
[10]
Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy[J]. Cancer Cell Int, 2005, 5(1): 18.
[11]
Roccaro AM, Vacca A, Ribatti D, et al. Bortezomib in the treatment of cancer[J]. Recent Pat Anticancer Drug Discov, 2006, 1(3): 397-403.
[12]
Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications[J].Blood, 2003, 101(6): 2377-2380.
[13]
Sonneveld P, Schmidt-Wolf IG, Van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phaseⅢ HOVON-65/GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30(24): 2946-2955.
[14]
Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study[J]. Lancet, 2010, 376(9758): 2075-2085.
[15]
Kaufman JL, Nooka A, Vrana M, et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study[J]. Cancer, 2010, 116(13): 3143-3151.
[16]
Reeder CB, Reece DE, Kukreti V, et al. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma[J]. Blood, 2010, 115(16): 3416-3417.
[17]
Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phaseⅢ trial[J]. J Clin Oncol, 2010, 28(30): 4621-4629.
